Skip to main content
Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Blocking ATP-sensitive potassium channel alleviates morphine tolerance by inhibiting HSP70-TLR4-NLRP3-mediated neuroinflammation

Fig. 6

Schematic model indicates that glibenclamide alleviates morphine tolerance by inhibiting HSP70 release and NLRP3 inflammasome activation. Morphine activates TLR4 by inducing the release of HSP70. The secretion of HSP70 is under the control of MOR/AKT/KATP/ERK signal pathway. Extracellular HSP70 induces the activation of microglia and upregulation of neuroinflammatory cytokines including IL-1β via TLR4-NLRP3 inflammasome pathway. Glibenclamide as a KATP channel blocker inhibits the release of HSP70 induced by morphine and suppresses the activation of NLRP3 inflammasome, consequently alleviating morphine tolerance

Back to article page